|
Synairgen in Drug Partnership Talks After Asthma Study Results
Businessweek Synairgen Plc (SNG) is in talks with potential partners following the results of a study of an experimental drug targeting infections that trigger asthma attacks, Chief Executive Officer Richard Marsden said. Synairgen is speaking with larger … |
View full post on asthma – Google News